rAAV-Mediated Gene Therapy Targeting CNS Disorders

Lester Suarez-Amaran; Christina Chatzi; Richard Jude Samulski; Inge Flier

doi:10.1007/978-3-031-89307-0_2

rAAV-Mediated Gene Therapy Targeting CNS Disorders

Lester Suarez-Amaran
, Christina Chatzi
, Richard Jude Samulski^*
, Inge Flier

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

5 Downloads (Pure)

Abstract

Central nervous system (CNS) disorders are the leading cause of disability and the second leading cause of death worldwide, with conditions such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and amyotrophic lateral sclerosis (ALS) having profound impacts on patients’ quality of life. These disorders impair motor, cognitive, and sensory functions, imposing significant emotional, social, and financial burdens on patients and caregivers [36, 56, 57]. This chapter will discuss the present set of tools of gene therapy that can be applied to these disorders.

Original language	English
Title of host publication	Translational Neuroscience
Subtitle of host publication	Fundamental Approaches for Neurological Disorders
Publisher	Springer
Pages	9-30
Number of pages	22
ISBN (Electronic)	9783031893070
ISBN (Print)	9783031893063
DOIs	https://doi.org/10.1007/978-3-031-89307-0_2
Publication status	Published - 1 Jan 2025
Externally published	Yes

Access to Document

10.1007/978-3-031-89307-0_2

978-3-031-89307-0_2Final published version, 819 KBLicence: Taverne

Cite this

@inbook{8708bb767f04404ab1b2a8637b311de7,

title = "rAAV-Mediated Gene Therapy Targeting CNS Disorders",

abstract = "Central nervous system (CNS) disorders are the leading cause of disability and the second leading cause of death worldwide, with conditions such as Parkinson{\textquoteright}s disease, Alzheimer{\textquoteright}s disease, epilepsy, and amyotrophic lateral sclerosis (ALS) having profound impacts on patients{\textquoteright} quality of life. These disorders impair motor, cognitive, and sensory functions, imposing significant emotional, social, and financial burdens on patients and caregivers [36, 56, 57]. This chapter will discuss the present set of tools of gene therapy that can be applied to these disorders.",

author = "Lester Suarez-Amaran and Christina Chatzi and Samulski, \{Richard Jude\} and Inge Flier",

note = "Publisher Copyright: {\textcopyright} 2025 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG.",

year = "2025",

month = jan,

day = "1",

doi = "10.1007/978-3-031-89307-0\_2",

language = "English",

isbn = "9783031893063",

pages = "9--30",

booktitle = "Translational Neuroscience",

publisher = "Springer",

address = "Singapore",

}

TY - CHAP

T1 - rAAV-Mediated Gene Therapy Targeting CNS Disorders

AU - Suarez-Amaran, Lester

AU - Chatzi, Christina

AU - Samulski, Richard Jude

AU - Flier, Inge

PY - 2025/1/1

Y1 - 2025/1/1

N2 - Central nervous system (CNS) disorders are the leading cause of disability and the second leading cause of death worldwide, with conditions such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and amyotrophic lateral sclerosis (ALS) having profound impacts on patients’ quality of life. These disorders impair motor, cognitive, and sensory functions, imposing significant emotional, social, and financial burdens on patients and caregivers [36, 56, 57]. This chapter will discuss the present set of tools of gene therapy that can be applied to these disorders.

AB - Central nervous system (CNS) disorders are the leading cause of disability and the second leading cause of death worldwide, with conditions such as Parkinson’s disease, Alzheimer’s disease, epilepsy, and amyotrophic lateral sclerosis (ALS) having profound impacts on patients’ quality of life. These disorders impair motor, cognitive, and sensory functions, imposing significant emotional, social, and financial burdens on patients and caregivers [36, 56, 57]. This chapter will discuss the present set of tools of gene therapy that can be applied to these disorders.

UR - https://www.scopus.com/pages/publications/105022220831

U2 - 10.1007/978-3-031-89307-0_2

DO - 10.1007/978-3-031-89307-0_2

M3 - Chapter

AN - SCOPUS:105022220831

SN - 9783031893063

SP - 9

EP - 30

BT - Translational Neuroscience

PB - Springer

ER -

rAAV-Mediated Gene Therapy Targeting CNS Disorders

Abstract

Access to Document

Other files and links

Fingerprint

Cite this